Norges Bank
ENTA icon

Norges Bank’s Enanta Pharmaceuticals ENTA Stock Holding History

Norges Bank’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-40,700
Closed -$234K – 1776
2024
Q4 		$234K Hold
40,700
– – ﹤0.01% 1823
2024
Q3 		$422K Hold
40,700
– – ﹤0.01% 1795
2024
Q2 		$528K Buy
+40,700
New +$549K ﹤0.01% 1874
2023
Q3 		– Sell
-150,614
Closed -$3.22M – 1990
2023
Q2 		$3.22M Buy
150,614
+28,000
+23% +$825K ﹤0.01% 1809
2023
Q1 		$4.96M Sell
122,614
-103,805
-46% -$4.96M ﹤0.01% 1760
2022
Q4 		$10.5M Buy
226,419
+66,600
+42% +$3.04M ﹤0.01% 1553
2022
Q3 		$8.29M Buy
159,819
+20,313
+15% +$1.19M ﹤0.01% 1599
2022
Q2 		$6.59M Hold
139,506
– – ﹤0.01% 1697
2022
Q1 		$9.93M Buy
139,506
+15,162
+12% +$987K ﹤0.01% 1703
2021
Q4 		$9.3M Buy
124,344
+14,408
+13% +$1.13M ﹤0.01% 1785
2021
Q3 		$6.25M Hold
109,936
– – ﹤0.01% 1891
2021
Q2 		$4.84M Sell
109,936
-18,978
-15% -$929K ﹤0.01% 1914
2021
Q1 		$6.36M Sell
128,914
-25,088
-16% -$1.25M ﹤0.01% 1880
2020
Q4 		$6.48M Sell
154,002
-5,692
-4% -$250K ﹤0.01% 1843
2020
Q3 		$7.31M Sell
159,694
-5,391
-3% -$261K ﹤0.01% 1800
2020
Q2 		$8.29M Sell
165,085
-46,047
-22% -$2.38M ﹤0.01% 1768
2020
Q1 		$10.9M Hold
211,132
– – ﹤0.01% 1575
2019
Q4 		$13M Hold
211,132
– – ﹤0.01% 1719
2019
Q3 		$12.7M Buy
211,132
+11,986
+6% +$890K ﹤0.01% 1694
2019
Q2 		$16.8M Buy
199,146
+10,845
+6% +$976K 0.01% 1597
2019
Q1 		$18M Buy
188,301
+87,975
+88% +$7.89M 0.01% 1564
2018
Q4 		$7.11M Buy
100,326
+13,078
+15% +$1M ﹤0.01% 1845
2018
Q3 		$7.46M Buy
+87,248
New +$8.74M ﹤0.01% 1897

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank's ENTA Position: Q1 2025 in Review

Norges Bank sold out of Enanta Pharmaceuticals (ENTA) in Q1 2025, closing a stake of 40,700 shares — an estimated $234K sold.

Norges Bank first reported a position in ENTA in Q3 2018 and held it in 23 quarters. The position peaked at $18M in Q1 2019. 109 funds tracked by Wall St. Rank hold ENTA as of Q1 2025.

  • Norges Bank reported no remaining Enanta Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Norges Bank sold 40,700 Enanta Pharmaceuticals shares in Q1 2025, an estimated $234K.
  • Norges Bank first reported a position in Enanta Pharmaceuticals in Q3 2018 and held it in 23 quarters.
  • Norges Bank's Enanta Pharmaceuticals position peaked at $18M in Q1 2019.
  • 109 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2025.

Based on Norges Bank's 13F filing for Q1 2025, filed 13 May 2025.